Phase 2b Study Identifies Dose-Response Signals for APPA in Knee Osteoarthritis, with Statistically Significant Benefits on Several Outcomes at the Higher Dose in Patients with Higher Baseline Pain. The study also finds a consistent dose-response relationship on pain and other symptom measures and a prespecified subgroup analysis support further clinical development of the investigational oral combination.
NBCD A/S and AKL Therapeutics today reported findings from a Phase 2b clinical study evaluating APPA, an investigational fixed-dose oral combination of apocynin and paeonol, in patients with knee osteoarthritis (OA), moderate-to-severe pain and features of nociplastic pain.
The findings, reported in an abstract at ACR Convergence 2026 (abstract 0636, Poster Session A, 8 November 2026), showed a consistent dose-response pattern across secondary pain measures and identified statistically significant benefits on several outcomes in a prespecified subgroup of patients with higher baseline pain. Although the study did not meet its primary endpoint in the overall population, the findings provide a rationale for further evaluation of APPA, particularly at the higher dose and in patients with a greater pain burden.
In a press release issued by the company, Asger Bihlet, Chief Scientific Officer of NBCD A/S, said: “The Phase 2b findings are encouraging, with a consistent dose-response pattern across several pain measures and particularly promising results in patients with higher baseline pain. Demonstration of pain and symptom benefit in OA clinical trials is very challenging, and the statistically significant findings, across several outcomes in this prespecified subgroup, provide an important direction for the program and support further development of APPA. Combined with the opportunity to optimize APPA’s formulation and drug exposure, these results give us a clear rationale for the next stage of clinical development.”
David Miles, Chief Executive Officer of AKL Therapeutics, said: “The Phase 2b findings provide a meaningful basis for the next stage of APPA’s development. The dose-response signals and the results in patients with higher baseline pain give us important questions to pursue as we refine the formulation, dose and target patient population. We believe this is a promising opportunity to advance a differentiated oral approach to osteoarthritis pain, and we look forward to evaluating its potential in further clinical studies.”
A full copy of the abstract can be found here.